Form 8-K - Current report:
SEC Accession No. 0001213900-25-059738
Filing Date
2025-06-30
Accepted
2025-06-30 17:09:33
Documents
14
Period of Report
2025-06-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0247627-8k_cero.htm   iXBRL 8-K 36196
2 FORM OF AMENDMENT TO THE SECURITIES PURCHASE AGREEMENT ea024762701ex10-2_cero.htm EX-10.2 42163
  Complete submission text file 0001213900-25-059738.txt   300444

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cero-20250625.xsd EX-101.SCH 3817
4 XBRL DEFINITION FILE cero-20250625_def.xml EX-101.DEF 26702
5 XBRL LABEL FILE cero-20250625_lab.xml EX-101.LAB 36885
6 XBRL PRESENTATION FILE cero-20250625_pre.xml EX-101.PRE 25326
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0247627-8k_cero_htm.xml XML 6006
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

EIN.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40877 | Film No.: 251093090
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)